Pasar al contenido principal

MECANISMOS DE ACCION DE LOS CANNABINOIDES SOBRE LA PROPAGACION DE AGENTES PATOGENICOS EN AMILOIDOPATIAS Y SINUCLEINOPATIAS

PID2020-113430RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Allosterism in the adenosine A2A and cannabinoid CB2 heteromer

  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Raïch, Iu|||0000-0001-6271-0495
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Lillo Jové, Jaume|||0000-0001-7712-0850
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
Background and Purpose: Allosterism is a regulatory mechanism for GPCRs that can be attained by ligand-binding or protein-protein interactions with another GPCR. We have studied the influence of the dimer interface on the allosteric properties of the A2A receptor and CB2 receptor heteromer. Experimental Approach: We have evaluated cAMP production, phosphorylation of signal-regulated kinases (pERK1/2), label-free dynamic mass redistribution, β-arrestin 2 recruitment and bimolecular fluorescence complementation assays in the absence and presence of synthetic peptides that disrupt the formation of the heteromer. Molecular dynamic simulations provided converging evidence that the heteromeric interface influences the allosteric properties of the A2AR-CB2R heteromer. Key Results: Apo A2AR blocks agonist-induced signalling of CB2R. The disruptive peptides, with the amino acid sequence of transmembrane (TM) 6 of A2AR or CB2R, facilitate CB2R activation, suggesting that A2AR allosterically prevents the outward movement of TM 6 of CB2R for G protein binding. Significantly, binding of the selective antagonist SCH 58261 to A2AR also facilitated agonist-induced activation of CB2R. Conclusions and Implications: It is proposed that the A2AR-CB2R heteromer contains distinct dimerization interfaces that govern its functional properties. The molecular interface between protomers of the A2AR-CB2R heteromer interconverted from TM 6 for apo or agonist-bound A2AR, blocking CB2R activation, to mainly the TM 1/7 interface for antagonist-bound A2AR, facilitating the independent opening of intracellular cavities for G protein binding. These novel results shed light on a different type of allosteric mechanism and extend the repertoire of GPCR heteromer signalling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The NADPH Link between the Renin Angiotensin System and the Antioxidant Mechanisms in Dopaminergic Neurons

  • Franco, Rafael|||0000-0003-2549-4919
  • Serrano-Marín, Joan|||0000-0001-9316-0721
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
The renin angiotensin system (RAS) has several components including signaling peptides, enzymes, and membrane receptors. The effort in characterizing this system in the periphery has led to the approval of a class of antihypertensives. Much less is known about RAS in the central nervous system. The production of RAS peptides and the expression of several RAS enzymes and receptors in dopaminergic neurons of the substantia nigra has raised expectations in the therapy of Parkinson's disease, a neurodegenerative condition characterized by lack of dopamine in the striatum, the motor control region of the mammalian brain. On the one hand, dopamine production requires reducing power. On the other hand, reducing power is required by mechanisms involved in REDOX homeostasis. This review focuses on the potential role of RAS in the regulation of neuronal/glial expression of glucose-6-phosphate dehydrogenase, which produces the NADPH required for dopamine synthesis and for reactive oxygen species (ROS) detoxification. It is known that transgenic expression of the gene coding for glucose-6-phosphate dehydrogenase prevents the death of dopaminergic nigral neurons. Signaling via angiotensin II G protein-coupled receptors, AT or AT, leads to the activation of protein kinase A and/or protein kinase C that in turn can regulate glucose-6- phosphate dehydrogenase activity, by Ser/Thr phosphorylation/dephosphorylation events. Long-term effects of AT or AT receptor activation may also impact on the concentration of the enzyme via activation of transcription factors that participate in the regulation of gene expression in neurons (or glia). Future research is needed to determine how the system can be pharmacologically manipulated to increase the availability of NADPH to neurons degenerating in Parkinson's disease and to neuroprotective glia.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Mechanism of μ-opioid receptor inhibition by orphan GPR88

  • Llinas del Torrent, Claudia
  • Raïch, Iu
  • Carrasco-Martinez, Berta
  • Lillo, Jaume
  • Gallo, María, 1989-
  • Andreu Martínez, David
  • Pardo Carrasco, Leonardo
  • Navarro, Gemma
From the approximately 800 members of the G protein-coupled receptor (GPCR) family, more than 100 remain orphans (oGPCRs). There is evidence indicating that some oGPCRs may carry out a physiological role independently from endogenous ligands; this includes forming heteromers with other GPCRs and altering their functional and pharmacological properties via allosteric interactions. Recent studies have shown that some of these oGPCRs, e.g. GPR88 and GPR139, allosterically inhibit opioid activity by interacting with the μ-opioid receptor (μOR). Here, we have focused on the characterization of the interaction between GPR88 and µOR and the allosteric mechanism of inhibition. We confirmed that GPR88 inhibits µOR function in striatal neuronal primary cultures. Moreover, using a peptide-interfering approach combined with biophysical and biochemical techniques, we identified that GPR88 and µOR interact via transmembrane helix 6. A combination of molecular dynamic simulations and site-directed mutagenesis have allowed to propose that the negative regulatory role of GPR88 on µOR is due to the Q2986.49 side chain of GPR88., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (PID2020-113430RB-I00, PID2022-140912OB-I00) and Generalitat de Catalunya (2021 SGR 00304). Work at MELIS-UPF supported by MCIN "María de Maeztu" program for units of excellence in R&D (CEX2018-000792-M). C.L.T. is recipient of a FPI Fellowship (BES-2017-081872) and B.C-M. is recipient of a FI Fellowship (2025 FI-1 00603). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by Barcelona Supercomputing Center (RES-BCV2025-1-0011).
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

  • Gioé Gallo, Claudia
  • Ortigueira Noya, Sandra
  • Brea Floriani, José Manuel
  • Raïch, Iu
  • Azuaje Guerrero, Jhonny Alberto
  • Paleo Pillado, María Rita
  • Majellaro, María
  • Loza García, María Isabel
  • Salas, Cristian O.
  • García Mera, Xerardo
  • Navarro, Gemma
  • Sotelo Pérez, Eddy
Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

A robust and efficient FRET-based assay for cannabinoid receptor ligands discovery

  • Navarro Brugal, Gemma
  • Sotelo Pérez, Eddy
  • Raïch, Iu
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Majellaro, María
The identification of new modulators for Cannabinoid Receptors (CBRs) has garnered significant attention in drug discovery over recent years, owing to their manifold pathophysiological implications. In the context of hit identification, the availability of robust and sensitive high-throughput screening assays is essential to enhance the likelihood of success. In this study, we present the development and validation of a Tag-lite® binding assay designed for screening hCB1/hCB2 binding, employing a dual fluorescent ligand, CELT-335. Representative ligands for CBRs, exhibiting diverse affinity and functional profiles, were utilized as reference compounds to validate the robustness and efficiency of the newly developed Tag-lite® binding assay protocol. The homogeneous format, coupled with the sensitivity and optimal performance of the fluorescent ligand CELT-335, establishes this assay as a viable and reliable method for screening in hit and lead identification campaigns
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB2 Agonists with Neuroprotective Effects

  • Prieto Díaz, Rubén
  • Gioé Gallo, Claudia
  • Ortigueira Noya, Sandra
  • García Mera, Xerardo
  • Azuaje Guerrero, Jhonny Alberto
  • Andújar Arias, Antonio
  • García Rey, Aitor
  • Graciano, Giovanni
  • Val García, Cristina
  • Martínez Rodríguez, Antón Leandro
  • Reza, David
  • Selas Lanseros, Asier
  • Francavilla, Fabio
  • Paleo Pillado, María Rita
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Sotelo Pérez, Eddy
This study presents the design, synthesis, and characterization of a novel series of structurally simple, selective, and functionally biased CB2 receptor (CB2R) agonists with potent anti-inflammatory and neuroprotective properties. These compounds were developed using a conformational restriction strategy to abolish CB1R binding, thereby enhancing CB2R selectivity. Pharmacological profiling identified ligands with distinct bias toward β-arrestin, MAPK, and G-protein signaling pathways. The series exhibits favorable drug-like properties, including high BBB permeability, low P-glycoprotein interaction, and microsomal stability. Representative compounds demonstrated neuroprotective activity in mouse primary neuronal assays and significantly reduced ROS and caspase levels in vitro, indicating mitigation of oxidative stress and apoptosis. In a neuron-like SH-SY5Y model expressing pathogenic mutations, they preserved neurite complexity in a CB2R-dependent manner. Collectively, these findings highlight the advantages of conformational restriction in transforming abused promiscuous, neurotoxic ligands into highly selective and efficacious agents for the treatment of neurodegenerative disorders, without CB1R-mediated psychoactive effects.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors

  • Franco, Rafael
  • Morales, Paula
  • Navarro, Gemma
  • Jagerovic, Nadine
  • Reyes-Resina, Irene
The classical terms agonists and antagonists for G protein coupled receptors (GPCRs) have often become misleading. Even the biased agonism concept does not describe all the possibilities already demonstrated for GPCRs. The cannabinoid CB receptor (CBR) emerged as a promising target for a variety of diseases. Reasons for such huge potential are centered around the way drugs sit in the orthosteric and/or exosites of the receptor. On the one hand, a given drug in a specific CBR conformation leads to a signaling cascade that differs qualitatively and/or quantitatively from that triggered by another drug. On the other hand, a given drug may lead to different signaling outputs in two different tissues (or cell contexts) in which the conformation of the receptor is affected by allosteric effects derived from interactions with other proteins or with membrane lipids. This highlights the pharmacological complexity of this receptor and the need to further unravel the binding mode of CBR ligands in order to fine-tune signaling effects and therapeutic propositions., This work was partially supported by AARFD-17-503612 grant of the US Alzheimer’s Association and by grants SAF 2017-84117-R, RTI 2018-094204-B-I00, RTI 2018-095544-B-I00 and PID 2020-113430RB-I00 funded by Spanish MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR”. PM is a postdoctoral fellow supported by the Juan de la Cierva Programme-MICIU (IJC 2019-042182-I). The research group of the University of Barcelona is considered of excellence (grup consolidat #2017 SGR 1497) by the Regional Catalonian Government, which does not provide any specific funding for reagents or for payment of services or Open Access fees, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling

  • Navarro, Gemma
  • Gómez-Autet, Marc
  • Morales, Paula
  • Biel Rebassa, Joan
  • Llinas del Torrent, Claudia
  • Jagerovic, Nadine
  • Pardo, Leonardo
  • Franco, Rafael
G protein-coupled receptors (GPCRs) exist within a landscape of interconvertible conformational states and in dynamic equilibrium between monomers and higher-order oligomers, both influenced by ligand binding. Here, we show that a homobivalent ligand formed by equal chromenopyrazole moieties as pharmacophores, connected by 14 methylene units, can modulate the dynamics of the cannabinoid CB2 receptor (CB2R) homodimerization by simultaneously binding both protomers of the CB2R-CB2R homodimer. Computational and pharmacological experiments showed that one of the ligand pharmacophores binds to the orthosteric site of one protomer, and the other pharmacophore to a membrane-oriented pocket between transmembranes 1 and 7 of the partner protomer. This results in unique pharmacological properties, including increased potency in Gi-mediated signaling and enhanced recruitment of β-arrestin. Thus, by modulating dimerization dynamics, it may be possible to fine-tune CB2R activity, potentially leading to improved therapeutic outcomes, We acknowledge the financial support from the Spanish Ministry of Science and Innovation with FEDER funds (PID2020-113430RB-I00, PID2021-126600OB-I00, PDC2022-133171-I00, PID2022-140912OB- I00, PID2021-127833OB-I00, PID2022-139197OA-I00) and Generalitat de Catalunya (2021 SGR 00304). C.L.T. is recipient of a FPI fellowship (BES-2017-081872) and M.G.-A. acknowledges the Universitat Autonoma de Barcelona for his predoctoral grant., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of the ghrelin and cannabinoid CB2 receptor heteromer functionality and marked upregulation in striatal neurons from offspring of mice under a high-fat diet

  • Lillo, Jaume
  • Lillo, Alejandro
  • Zafra, David A.
  • Miralpeix Monclús, Cristina
  • Rivas-Santisteban, Rafael
  • Casals i Farré, Núria
  • Navarro, Gemma
  • Franco, Rafael
This work was partially supported by the AARFD-17-503612 grant the US Alzheimer’s Association, and by grants SAF2017-84117-R and PID2020-113430RB-I00 from the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU; or equivalent) and Spanish Agencia Estatal de Investigación (AEI); they include UE FEDER funds., Cannabinoids have been reported as orexigenic, i.e., as promoting food intake that, among others, is controlled by the so-called “hunger” hormone, ghrelin. The aim of this paper was to look for functional and/or molecular interactions between ghrelin GHSR1a and cannabinoid CB2 receptors at the central nervous system (CNS) level. In a heterologous system we identified CB2-GHSR1a receptor complexes with a particular heteromer print consisting of impairment of CB2 receptor/Gi-mediated signaling. The blockade was due to allosteric interactions within the heteromeric complex as it was reverted by antagonists of the GHSR1a receptor. Cannabinoids acting on the CB2 receptor did not affect cytosolic increases of calcium ions induced by ghrelin acting on the GHSR1a receptor. In situ proximity ligation imaging assays confirmed the expression of CB2-GHSR1a receptor complexes in both heterologous cells and primary striatal neurons. We tested heteromer expression in neurons from offspring of high-fat-diet mouse mothers as they have more risk to be obese. Interestingly, there was a marked upregulation of those complexes in striatal neurons from siblings of pregnant female mice under a high-fat diet., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mechanism of μ-opioid receptor inhibition by orphan GPR88

  • Llinas del Torrent, Claudia
  • Raïch, Iu
  • Carrasco-Martinez, Berta
  • Lillo, Jaume
  • Gallo, María, 1989-
  • Andreu Martínez, David
  • Pardo Carrasco, Leonardo
  • Navarro, Gemma
From the approximately 800 members of the G protein-coupled receptor (GPCR) family, more than 100 remain orphans (oGPCRs). There is evidence indicating that some oGPCRs may carry out a physiological role independently from endogenous ligands; this includes forming heteromers with other GPCRs and altering their functional and pharmacological properties via allosteric interactions. Recent studies have shown that some of these oGPCRs, e.g. GPR88 and GPR139, allosterically inhibit opioid activity by interacting with the μ-opioid receptor (μOR). Here, we have focused on the characterization of the interaction between GPR88 and µOR and the allosteric mechanism of inhibition. We confirmed that GPR88 inhibits µOR function in striatal neuronal primary cultures. Moreover, using a peptide-interfering approach combined with biophysical and biochemical techniques, we identified that GPR88 and µOR interact via transmembrane helix 6. A combination of molecular dynamic simulations and site-directed mutagenesis have allowed to propose that the negative regulatory role of GPR88 on µOR is due to the Q2986.49 side chain of GPR88., We acknowledge the financial support from the Spanish Ministry of Economy and Innovation with FEDER funds (PID2020-113430RB-I00, PID2022-140912OB-I00) and Generalitat de Catalunya (2021 SGR 00304). Work at MELIS-UPF supported by MCIN "María de Maeztu" program for units of excellence in R&D (CEX2018-000792-M). C.L.T. is recipient of a FPI Fellowship (BES-2017-081872) and B.C-M. is recipient of a FI Fellowship (2025 FI-1 00603). The authors thankfully acknowledge the computer resources at MareNostrum and the technical support provided by Barcelona Supercomputing Center (RES-BCV2025-1-0011).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB Receptor via the Lipid Bilayer

  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Gómez-Autet, Marc|||0000-0002-6133-988X
  • Quintana García, Aleix|||0000-0003-4472-5129
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
Molecular dynamic (MD) simulations have become a common tool to study the pathway of ligand entry to the orthosteric binding site of G protein-coupled receptors. Here, we have combined MD simulations and site-directed mutagenesis to study the binding process of the potent JWH-133 agonist to the cannabinoid CB receptor (CBR). In CBR, the N-terminus and extracellular loop 2 fold over the ligand binding pocket, blocking access to the binding cavity from the extracellular environment. We, thus, hypothesized that the binding pathway is a multistage process consisting of the hydrophobic ligand diffusing in the lipid bilayer to contact a lipid-facing vestibule, from which the ligand enters an allosteric site inside the transmembrane bundle through a tunnel formed between TMs 1 and 7 and finally moving from the allosteric to the orthosteric binding cavity. This pathway was experimentally validated by the Ala282 7.36 Phe mutation that blocks the entrance of the ligand, as JWH-133 was not able to decrease the forskolin-induced cAMP levels in cells expressing the mutant receptor. This proposed ligand entry pathway defines transient binding sites that are potential cavities for the design of synthetic modulators.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Expression of Cellular Prion Protein, PrPC, Favors pTau Propagation and Blocks NMDAR Signaling in Primary Cortical Neurons

  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
  • Raïch, Iu|||0000-0001-6271-0495
  • Aguinaga Andrés, David|||0000-0003-2506-7204
  • Saura Antolín, Carlos|||0000-0003-3692-5657
  • Franco, Rafael|||0000-0003-2549-4919
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
Background: The N-methyl-D-aspartate receptor (NMDAR) is a target in current treatments for Alzheimer's disease (AD). The human prion protein (PrPC) has an important role in the pathophysiology of AD. We hypothesized that PrPC modulates NMDA signaling, thus being a process associated with Alzheimer's disease. Methods: NMDAR signaling was characterized in the absence or presence of PrPC in cAMP level determination, mitogen-activated protein kinase (MAPK) pathway and label-free assays in homologous and heterologous systems. Bioluminescence resonance energy transfer was used to detect the formation of NMDAR-PrPC complexes. AXIS™ Axon Isolation Devices were used to determine axonal transport of Tau and pTau proteins in cortical primary neurons in the absence or presence of PrPC. Finally, proximity ligation assays were used to quantify NMDA-PrPC complex formation in neuronal primary cultures isolated from APP transgenic mice, an Alzheimer's disease model expressing the Indiana and Swedish mutated version of the human amyloid precursor protein (APP). Results: We discovered a direct interaction between the PrPC and the NMDAR and we found a negative modulation of NMDAR-mediated signaling due to the NMDAR-PrPC interaction. In mice primary neurons, we identified NMDA-PrPC complexes where PrPC was capable of blocking NMDAR-mediated effects. In addition, we observed how the presence of PrPC results in increased neurotoxicity and neuronal death. Similarly, in microglial primary cultures, we observed that PrPC caused a blockade of the NMDA receptor link to the MAPK signaling cascade. Interestingly, a significant increase in NMDA-PrPC macromolecular complexes was observed in cortical neurons isolated from the APP transgenic model of AD. Conclusions: PrPC can interact with the NMDAR, and the interaction results in the alteration of the receptor functionality. NMDAR-PrPC complexes are overexpressed in neurons of APP mouse brain. In addition, PrPC exacerbates axonal transport of Tau and pTau proteins.